AInvest

Moderna

Moderna Plummets 6.1%: Earnings Miss and Cost-Cutting Spark Investor Exodus

Summary • <a data-code="MRNA" data-position="stock.1" data-marketid="185" data-stockname="Moderna" data-type="stock" href="#*f:MRNA:sc*#">Moderna</a> (MRNA) slashes 10% of workforce and cuts 2025 revenue guidance after Q2 earnings • RSV vaccine underperforms expectations, while operating expenses fall 27% • Biotech sector sees mixed signals as <a data-code="AMGN" data-position="stock.2" data-marketid="185" data-stockname="Amgen" data-type="stock" href="#*f:AMGN:sc*#">Amgen</a> (AMGN) edges up 0.77%

Moderna’s shares cratered nearly 6.1% in intraday trading as a combination of revenue guidance reductions, workforce cuts, and underwhelming RSV vaccine sales triggered a sharp sell-off. The stock traded as low as $26.78, nearly 6% below its 52-week low of $23.15, amid growing concerns about its post-pandemic pipeline and cost-cutting measures. <visualization data="{&quot;components&quot;: [{&quot;show_type&quot;: &quot;container2&quot;, &quot;uuid&quot;: &quot;bce44c3e-1613-4f46-bdd0-c6ebe393a797&quot;}, {&quot;category&quot;: &quot;generic&quot;, &quot;chart_type&quot;: &quot;&quot;, &quot;config&quot;: {&quot;image&quot;: &quot;https://lh-prod-mid-pub-newsf10.s3.amazonaws.com/logo/MRNA.png&quot;, &quot;marketTag&quot;: &quot;NASDAQ&quot;, &quot;show_type_id&quot;: 702, &quot;tradeClass&quot;: &quot;intraday&quot;, &quot;title&quot;: &quot;K\u7ebf\u56feV2&quot;, &quot;fsType&quot;: &quot;closed&quot;, &quot;showBottom&quot;: true, &quot;showCodeContrast&quot;: false, &quot;score&quot;: 20, &quot;show_type&quot;: &quot;kline3&quot;, &quot;variety&quot;: &quot;stock&quot;, &quot;scoreRuleNames&quot;: &quot;&quot;, &quot;tradeStatus&quot;: &quot;trading&quot;, &quot;codeName&quot;: &quot;Name&quot;, &quot;klineDefaultType&quot;: &quot;fs&quot;, &quot;title_config&quot;: {&quot;config&quot;: {&quot;display&quot;: true, &quot;display2&quot;: false, &quot;txt_style&quot;: 0, &quot;url&quot;: &quot;&quot;}, &quot;data&quot;: {&quot;h1&quot;: &quot;MRNA Trend&quot;, &quot;h2&quot;: &quot;&quot;}, &quot;show_type&quot;: &quot;title1&quot;}}, &quot;data&quot;: {&quot;chunks_info&quot;: &quot;[]&quot;, &quot;code_count&quot;: 1, &quot;columns&quot;: [{&quot;index_name&quot;: &quot;code&quot;, &quot;key&quot;: &quot;code&quot;, &quot;label&quot;: &quot;hq_code&quot;, &quot;source&quot;: &quot;fixed_index&quot;, &quot;type&quot;: &quot;STR&quot;}, {&quot;domain&quot;: &quot;abs_\u56fd\u9645\u7f8e\u80a1\u9886\u57df&quot;, &quot;feKey&quot;: &quot;Ticker&quot;, &quot;index_name&quot;: &quot;Ticker&quot;, &quot;key&quot;: &quot;Ticker&quot;, &quot;label&quot;: &quot;code&quot;, &quot;origin_index&quot;: &quot;stock code&quot;, &quot;source&quot;: &quot;fixed_index&quot;, &quot;type&quot;: &quot;STR&quot;, &quot;unit&quot;: &quot;&quot;}, {&quot;domain&quot;: &quot;abs_\u56fd\u9645\u7f8e\u80a1\u9886\u57df&quot;, &quot;feKey&quot;: &quot;Name&quot;, &quot;index_name&quot;: &quot;Name&quot;, &quot;key&quot;: &quot;Name&quot;, &quot;label&quot;: &quot;name&quot;, &quot;origin_index&quot;: &quot;stock name&quot;, &quot;source&quot;: &quot;fixed_index&quot;, &quot;type&quot;: &quot;STR&quot;, &quot;unit&quot;: &quot;&quot;}, {&quot;feKey&quot;: &quot;Date&quot;, &quot;index_name&quot;: &quot;Date&quot;, &quot;key&quot;: &quot;Date&quot;, &quot;label&quot;: &quot;date&quot;, &quot;origin_index&quot;: &quot;Date&quot;, &quot;type&quot;: &quot;DATE&quot;}, {&quot;domain&quot;: &quot;abs_\u56fd\u9645\u7f8e\u80a1\u9886\u57df&quot;, &quot;feKey&quot;: &quot;Closing Price&quot;, &quot;index_name&quot;: &quot;Closing Price&quot;, &quot;key&quot;: &quot;Closing Price&quot;, &quot;label&quot;: &quot;NoIndent&quot;, &quot;source&quot;: &quot;&quot;, &quot;timestamp&quot;: &quot;&quot;, &quot;type&quot;: &quot;DOUBLE&quot;, &quot;unit&quot;: &quot;USD&quot;}, {&quot;index_name&quot;: &quot;market_code&quot;, &quot;key&quot;: &quot;market_code&quot;, &quot;type&quot;: &quot;STR&quot;}], &quot;condition&quot;: &quot;[{\&quot;sonSize\&quot;:2,\&quot;opName\&quot;:\&quot;and\&quot;,\&quot;relatedSize\&quot;:0},{\&quot;sonSize\&quot;:0,\&quot;indexName\&quot;:\&quot;\u56fd\u9645\u7f8e\u80a1@stock code\&quot;,\&quot;indexProperties\&quot;:[\&quot;EQUAL MRNA.O\&quot;],\&quot;indexPropertiesMap\&quot;:{\&quot;EQUAL\&quot;:\&quot;MRNA.O\&quot;},\&quot;domain\&quot;:\&quot;abs_\u56fd\u9645\u7f8e\u80a1\u9886\u57df\&quot;,\&quot;relatedSize\&quot;:0},{\&quot;sonSize\&quot;:0,\&quot;indexName\&quot;:\&quot;\u56fd\u9645\u7f8e\u80a1@Closing Price\&quot;,\&quot;indexProperties\&quot;:[\&quot;\u8d77\u59cb\u4ea4\u6613\u65e5\u671f 20250801\&quot;,\&quot;\u622a\u6b62\u4ea4\u6613\u65e5\u671f 20250801\&quot;],\&quot;indexPropertiesMap\&quot;:{\&quot;\u8d77\u59cb\u4ea4\u6613\u65e5\u671f\&quot;:\&quot;20250801\&quot;,\&quot;\u622a\u6b62\u4ea4\u6613\u65e5\u671f\&quot;:\&quot;20250801\&quot;},\&quot;domain\&quot;:\&quot;abs_\u56fd\u9645\u7f8e\u80a1\u9886\u57df\&quot;,\&quot;relatedSize\&quot;:0}]&quot;, &quot;dataSize&quot;: 1, &quot;datas&quot;: [{&quot;code&quot;: &quot;MRNA&quot;, &quot;Ticker&quot;: &quot;MRNA.O&quot;, &quot;market_code&quot;: &quot;185&quot;, &quot;Closing Price&quot;: &quot;27.82&quot;, &quot;Date&quot;: &quot;20250801&quot;, &quot;Name&quot;: &quot;Moderna&quot;}], &quot;meta&quot;: {&quot;extra&quot;: {}}, &quot;row_count&quot;: 1, &quot;status_code&quot;: 0, &quot;status_msg&quot;: &quot;ok&quot;}, &quot;data_config&quot;: {&quot;data_ext_params&quot;: {&quot;merge_repeat&quot;: false, &quot;expand_index&quot;: false, &quot;data_add&quot;: 0, &quot;add_index&quot;: 0}, &quot;query_type&quot;: &quot;intusstock&quot;}, &quot;kline&quot;: true, &quot;renderBy&quot;: &quot;rule&quot;, &quot;show_type&quot;: &quot;jgyKline3&quot;, &quot;support_refresh&quot;: false, &quot;unique_key&quot;: &quot;8f3f38157b25557b&quot;, &quot;uuid&quot;: &quot;f91176209de2016d&quot;, &quot;title_config&quot;: {&quot;config&quot;: {&quot;display&quot;: true, &quot;display2&quot;: false, &quot;txt_style&quot;: 0, &quot;url&quot;: &quot;&quot;}, &quot;data&quot;: {&quot;h1&quot;: &quot;MRNA Trend&quot;, &quot;h2&quot;: &quot;&quot;}, &quot;show_type&quot;: &quot;title1&quot;}}], &quot;global&quot;: {&quot;query_type&quot;: &quot;intusstock&quot;}, &quot;page&quot;: {&quot;layout&quot;: {&quot;layout_data&quot;: &quot;[{\&quot;children\&quot;: [{\&quot;uuid\&quot;: \&quot;f91176209de2016d\&quot;, \&quot;children\&quot;: [], \&quot;showType\&quot;: \&quot;\&quot;}], \&quot;showType\&quot;: \&quot;container2\&quot;, \&quot;uuid\&quot;: \&quot;bce44c3e-1613-4f46-bdd0-c6ebe393a797\&quot;}]&quot;}, &quot;render_for&quot;: &quot;aigc&quot;}, &quot;query_condition&quot;: {&quot;model_condition&quot;: null, &quot;uuids&quot;: [&quot;bce44c3e-1613-4f46-bdd0-c6ebe393a797&quot;, &quot;f91176209de2016d&quot;], &quot;domain&quot;: &quot;intusstock&quot;, &quot;query&quot;: null}, &quot;model_condition&quot;: null, &quot;model&quot;: null, &quot;data_config&quot;: {&quot;data_ext_params&quot;: {&quot;merge_repeat&quot;: false, &quot;expand_index&quot;: false, &quot;data_add&quot;: 0, &quot;add_index&quot;: 0}, &quot;query_type&quot;: &quot;intusstock&quot;}, &quot;answer_list&quot;: null, &quot;title&quot;: null}"></visualization> Revenue Outlook Cut and Workforce Reduction Drive Sharp Decline Moderna’s Q2 earnings report revealed a 41% year-over-year revenue drop to $142 million, driven by declining demand for its flagship Covid-19 vaccine and underwhelming RSV sales. The company cut its 2025 revenue guidance by $300 million, citing delayed U.K. vaccine shipments and reduced demand for its RSV shot. CEO Stephane Bancel announced a 10% global workforce reduction to offset declining sales, signaling a strategic pivot toward cost-cutting. Meanwhile, CFO Jamey Mock emphasized that the U.K. shipment delay—a $300 million impact—was a timing issue, not a revenue loss, but investors remain skeptical about Moderna’s ability to diversify its mRNA pipeline beyond vaccines.

Biotech Sector Splits as BioNTech Gains Momentum While Moderna’s struggles highlight the fragility of vaccine-centric business models, sector peer <a data-code="BNTX" data-position="stock.3" data-marketid="185" data-stockname="BioNTech" data-type="stock" href="#*f:BNTX:sc*#">BioNTech</a> (BNTX) continues to outperform, with its shares up nearly 30% year-to-date. BioNTech’s focus on oncology, including its bispecific antibody deal with Bristol Myers Squibb, contrasts with Moderna’s vaccine-heavy approach. Amgen (AMGN), the sector’s leader, edged up 0.77%, underscoring the market’s preference for diversified, high-margin biologics over single-product bets.

Bearish Technicals and Volatile Options Signal Aggressive Short-Side Opportunities • MACD: 0.89 (below signal line 1.29), bearish divergence • RSI: 34.31 (oversold territory) • 200-day MA: $35.24 (well above current price) • <a data-code="BINI" data-position="stock.4" data-marketid="186" data-stockname="Bollinger" data-type="stock" href="#*f:BINI:sc*#">Bollinger</a> Bands: $29.49–$35.36 (price near lower band) • Kline pattern: Short-term bearish trend, long-term ranging

Moderna’s technicals paint a bearish picture, with RSI in oversold territory and price near Bollinger Band lows. The YieldMax MRNA Option Income Strategy ETF (\<strong\>MRNY\</strong\>) plummeted 6.1% alongside the stock, signaling leveraged ETF pressure. Two options stand out for short-side exposure:

• \<strong\>MRNA20250808P27\</strong\> (Put): Strike $27, Expiry 8/8, IV 66.87%, Delta -0.38, Theta -0.0035, Gamma 0.139, Turnover 73,095 - High leverage ratio (35.92%) and gamma (0.139) suggest strong sensitivity to price drops - Projected payoff: $0.26 per share (27.76 → 25.37) = $0.26 gain • \<strong\>MRNA20250815P27\</strong\> (Put): Strike $27, Expiry 8/15, IV 66.03%, Delta -0.397, Theta -0.0123, Gamma 0.104, Turnover 19,253 - Moderate IV and high gamma (0.104) for time decay advantage - Projected payoff: $0.26 per share (27.76 → 25.06) = $0.26 gain

Break Below $27.11 Triggers Strategic Short-Positioning Moderna’s near-term outlook hinges on its ability to stabilize its mRNA pipeline and execute cost-cutting without sacrificing R&D momentum. Key levels to watch include the 200-day MA at $35.24 and critical support at $27.11 (30D pivot). The sector leader Amgen (\<strong\>AMGN\</strong\>) rose 0.77%, highlighting the market’s preference for diversified biologics. Aggressive traders should target a breakdown below $27.11 with \<strong\>MRNA20250808P27\</strong\> as the primary short vehicle. For a conservative approach, monitor the 52-week low at $23.15 as a final guardrail.<img src=https://cdn.ainvest.com/aigc/hxcmp/images/compress-1b1458b128c20001.png style="max-width: 100%;">